ATB STREP 5对肺炎链球菌药敏试验结果判读的缺陷性分析

Defect analysis of ATB STREP 5 kit in the susceptibility test of Streptococcus pneumoniae

目的探讨ATB STREP 5肺炎链球菌药敏试剂盒在用于肺炎链球菌药敏结果判读中存在的缺陷。方法以临床实验室标准化协会(CLSI)M100-S23文件提供的肺炎链球菌对应抗菌药物折点为标准,对ATB STREP 5试剂盒抗菌药物覆盖情况与各抗菌药物折点浓度进行对比分析。结果 ATB STREP 5试剂盒不包括CLSI推荐的碳青霉烯类和噁唑烷酮类等抗菌药物。ATB STREP 5试剂盒提供的11种抗菌药物中,有9种抗菌药物折点与CLSI M100-S23文件推荐的抗菌药物折点不一致,可能导致临床药敏报告出现假耐药的情况。结论在现行CLSI参考标准下,单独使用ATB STREP 5试剂盒进行肺炎链球菌药敏试验将产生较大误差甚至错误,必须联合使用其他药敏试验方法进行修正后方可发出报告。

Objective To explore the defects of ATB STREP 5kit in the susceptibility test of Streptococcus pneumoniae.Methods The varieties and breakpoint concentrations of antibiotics included in ATB STREP 5kit were analyzed by using the breakpoint concentrations of anti-Streptococcus pneumonia drugs recommend in CLSI document M100-S23 as standard.Results ATB STREP 5kit did not include carbapenems and oxazolidinone antibacterial drugs that were recommended by CLSI.Among 11 kinds of antibacterial drugs included in ATB STREP 5kit,there were 9kinds of antibacterial drugs having different breakpoint concentrations compared with CLSI M100-S23 standard.These defects might lead to false resistant results in reports.Conclusion According to current CLSI reference standards,if ATB STREP 5kit was the single method used for susceptibility detection of Streptococcus pneumonia,errors even mistakes would occur.The susceptibility results of Streptococcus pneumonia detected by ATB STREP 5kit should be corrected by other methods before reporting.